All eyes on Prescient Therapeutics as it enters into trading halt

• Placement opportunity for sophisticated and wholesale investors
• SPP and placement targeting $8 million
• Finds to advance ongoing development of PTX-100
• Biotech one of the strongest-performing sectors of 2026

Prescient Therapeutics (ASX:PTX) entered into a trading halt this morning and opened a placement opportunity for sophisticated and wholesale investors.

Reach Markets is the lead manager on this offer, which inclusive of the share purchase plan (SPP) and placement, is looking to raise $8 million.

The funds will be used to advance the ongoing development of specialist candidate PTX-100 beyond a Dose Optimisation Committee meeting scheduled for December 2026 and into the next phase of development.

The right asset at the right moment in biotech market running hot

Biotech has been one of the strongest-performing sectors of 2026, fuelling dealmaking across the market. M&A in the sector has roughly doubled in 12 months, hitting around US$84 billion in the first quarter of 2026 alone.

Behind the surge, large and mid-tier pharma face a wave of patent expiries and they are competing hard for de-risked, high-margin assets that come with market exclusivity.

That is precisely the profile Prescient Therapeutics is building around its lead therapy, PTX-100, targeting a rare form of blood cancer called cutaneous T-cell lymphoma (CTCL).

Significant Near-Term Milestones

A Dose Optimisation Committee review is the next major milestone and securing a recommended dose would be a significant de-risking moment for the company.

On top of that, PTX-100 holds FDA Fast Track designation, giving the company greater access to regulators and raising the possibility that the next phase of trials (Phase 2b) could be structured as a registration study – opening an accelerated pathway to market.

Linked with market exclusivity through Orphan Drug Designations in the US (seven years) and EU (10 years), PTX has the potential to offer all three characteristics that mid- and big-tier pharma are competing for.

A Comparison Worth Noting

In August 2026, Sobi acquired global rights to Innate Pharma’s CTCL drug lacutamab in a deal worth up to US$580 million (roughly A$815 million) – US$75 million upfront, US$40 million in near-term milestones, up to US$465 million in later milestones, plus double-digit royalties.

Notably, that drug targets Sézary syndrome, a rare CTCL subtype making up only around five per cent of CTCL cases – Prescient’s CTCL therapy covers ~64% of the market, more than 10x lacutamab.

Prescient’s Phase 2a trial aims to replicate its earlier Phase 1b results, in which PTX-100 delivered strong clinical results including 100% halt or reversal of cancer in evaluable CTCL patients with zero drug-related serious adverse events in a patient population with limited treatment options and a cancer that many clinicians consider a “death sentence” in advanced stages.

For a company valued around $70 million in a space where $815 million deals are being struck for a market roughly 10x smaller, the setup is striking.

CEO James McDonnell has already been in discussions, with mid and large-tier pharma showing interest in exactly this kind of asset. None of this guarantees a deal or an immediate dose confirmation – but if Prescient can replicate its Phase 1b data, the potential upside is significant.

PTX was steady at 6.8¢ . Mkt cap $71.50M.

Join the discussion: See what HotCopper users are saying about Prescient Therapeutics now and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.